18850 - Human Photoallergy Test

Sunscreening Agents Clinical Trial

Official title:

Human Photoallergy Test

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02751463
• Other study ID #: 18850
• Status: Completed
• Phase: N/A
• Start date: May 9, 2016
• Est. completion date: July 1, 2016

Study information

• Verified date: December 2018
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the potential of a test material to produce a photoallergic response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: July 1, 2016
• Est. primary completion date: July 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• be male or female between the ages of 18 and 60 inclusive;

• be lightly pigmented (Fitzpatrick Skin Type I, II, III);

• have read and signed the written Informed Consent Form and have completed a Health Insurance Portability and Accountability Act (HIPAA) Authorization Form in conformance with 45CFR Parts 160 and 164;

• be in general good health as determined by the subject's medical history and in the discretion of the investigator.

Exclusion Criteria:

• have a visible sunburn;

• have a history of sun hypersensitivity/photosensitivity or photosensitive dermatoses;

• have a known hypersensitivity or allergy against any of the active and non-active ingredients of the investigational products.

• subjects who are employees of the CRO and/or Bayer or is a household member of an employee

Related Conditions & MeSH terms

• Dermatitis, Photoallergic
• Sunscreening Agents

Intervention

Drug:
• Sunscreening Sport Spray Rest (BAY987519)
50 µl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3µl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )

Other:
• Untreated skin
One site is patched without treatment as control

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Intensity of skin reactions is evaluated by 5 point grading scale		Up to 72 hours

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer products.